New Delhi: In the aftermath of a price control order by the National Pharmaceutical Pricing Authority (NPPA), the association of global medical technology companies, Medical Technology Association of India (MTaI) has stated that it is for greater patient access, and respects any decision made to that end.
MTaI, however, also clearly mentioned in its statement that it does not support the price control. “The Government wanted us to provide a proposal for self-regulation and we were constantly engaged with them. Post facto, we feel we could have been heard better, and we expected the regulator to have waited for our preliminary proposal that was committed in our meeting last week before this decision,” read the statement from the MTaI that was released on the evening of 18th August.
“We had, in fact, shared with the NPPA our initial proposal for classification into 8-9 different categories. We strongly feel that there was merit in looking at different categories to classify and allow free market economy principles for companies to compete,” mentioned the statement further.
Since there is no emergency here, we are surprised by the use of Para 19 while we were engaged with the NPPA productively on some form of self-regulation, stated MTaI.